At the Limits - Leading Medical Education
@atthelimits.bsky.social
‘At the Limits’ has been leading medical education for over 25 years with events in multiple disease areas across the globe.
Reposted by At the Limits - Leading Medical Education
Giuseppe Curigliano and Aditya Bardia share some thoughts re DESITNY-Breast06 #bcsm dailynews.ascopubs.org/do/destiny-b...
DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive Metastatic Breast Cancer. How Do These Results Impact Practice for All Patients?
In DESTINY-Breast06, T-DXd demonstrated a statistically significant and clinically meaningful improvement in PFS compared with treatment of physician's choice in patients with HR-positive, HER2-low me...
dailynews.ascopubs.org
November 21, 2024 at 3:14 PM
Giuseppe Curigliano and Aditya Bardia share some thoughts re DESITNY-Breast06 #bcsm dailynews.ascopubs.org/do/destiny-b...
Reposted by At the Limits - Leading Medical Education
Breast cancer drug blocked for NHS use in England and Wales after talks collapse
Breast cancer drug blocked for NHS use in England and Wales after talks collapse
National Institute for Health and Care Excellence unable to reach price agreement with manufacturers of Enhertu
A breast cancer charity has said it was “beyond devastated” that talks to make a life-extending drug available on the NHS to women with a…
dlvr.it
November 19, 2024 at 9:10 PM
Breast cancer drug blocked for NHS use in England and Wales after talks collapse